公开(公告)号：US12029780B2

公开(公告)日：2024-07-09

申请号：US17549017

申请日：2021-12-13

申请人： OPKO BIOLOGICS LTD.

发明人： Fuad Fares ,  Udi Eyal Fima

IPC分类号： A61K38/27 ,  A61K38/24 ,  A61K47/00 ,  A61K47/02 ,  A61K47/12 ,  C07K14/475 ,  C07K14/505 ,  C07K14/555 ,  C07K14/59 ,  C07K14/61 ,  C07K19/00 ,  G01N33/74

CPC分类号： A61K38/27 ,  A61K38/24 ,  A61K47/02 ,  A61K47/12 ,  C07K14/505 ,  C07K14/555 ,  C07K14/59 ,  C07K14/61 ,  G01N33/74 ,  C07K2319/00 ,  C07K2319/31 ,  G01N2333/65 ,  G01N2800/52

摘要： CTP-modified human growth hormone polypeptides and pharmaceutical formulations and pharmaceutical compositions comprising the same and methods of producing, and using the same are disclosed.

公开(公告)号：US20240181011A1

公开(公告)日：2024-06-06

申请号：US18035249

申请日：2021-11-04

申请人： ethris GmbH

发明人： Carsten Rudolph ,  Christian Plank ,  Thomas Langenickel ,  Anna Macht ,  Kristin Lohmer

IPC分类号： A61K38/21 ,  A61K48/00 ,  A61P31/14 ,  C07K14/555

CPC分类号： A61K38/21 ,  A61K38/212 ,  A61K38/215 ,  A61K48/0075 ,  A61P31/14 ,  C07K14/555

摘要： The present invention relates to pharmaceutical compositions comprising an mRNA encoding an IFN-λ polypeptide for use in treating a viral-induced disorder, preferably a viral-induced respiratory disorder, such as COVID-19.

公开(公告)号：US20240018207A1

公开(公告)日：2024-01-18

申请号：US18027675

申请日：2021-09-22

申请人： Southlake Pharmaceuticals, Inc.

发明人： Yuhua George Zhang ,  Wendy Wanjin Tang

IPC分类号： C07K14/555 ,  C12N15/63 ,  A61P31/14

CPC分类号： C07K14/555 ,  C07K2319/30 ,  A61P31/14 ,  C12N15/63

摘要： The invention provides novel Fc-fusion proteins of interferon tau and compositions thereof, methods of their preparation and therapeutic use thereof in treating coronavirus (e.g., COVID-19 virus/SARS-CoV-2 and hCoV229E) viral infections, and related diseases and conditions.

公开(公告)号：US20230391844A1

公开(公告)日：2023-12-07

申请号：US18328327

申请日：2023-06-02

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Jiaxi WU ,  Supriya PATEL ,  Tong ZHANG ,  Nicolin BLOCH ,  Eric SMITH ,  Chia-Yang LIN ,  Vidur GARG ,  Erica ULLMAN

IPC分类号： C07K14/555 ,  A61P35/00 ,  C07K14/715

CPC分类号： C07K14/555 ,  A61P35/00 ,  C07K14/7155 ,  A61K38/00

摘要： The present disclosure provides IL2 proproteins comprising an IL2 moiety that is masked with an IL2Rα moiety and a protease-cleavable linker, configured such that the IL2Rα moiety is released from the IL2 moiety upon the action of a protease, e.g., at a tumor site. The IL2 proproteins optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor-associated antigen and directs the proprotein to a tumor site. The disclosure further provides pharmaceutical compositions comprising the IL2 proproteins, and methods of use of the IL2 proproteins in therapy, as well as nucleic acids encoding the IL2 proproteins, recombinant cells that express the IL2 proproteins and methods of producing the IL2 proproteins.

公开(公告)号：US20230279137A1

公开(公告)日：2023-09-07

申请号：US18152969

申请日：2023-01-11

申请人： EVOTEC INTERNATIONAL GmbH ,  SANOFI

发明人： Antoine ALAM

IPC分类号： C07K16/28 ,  C07K14/555 ,  C12N15/63 ,  A61P31/20

CPC分类号： C07K16/2878 ,  C07K14/555 ,  C12N15/63 ,  A61P31/20 ,  C07K2317/565 ,  C07K2317/55

摘要： The present invention relates to novel interferon-associated antigen binding proteins as well as nucleic acids, vectors and vector systems encoding such interferon-associated antigen binding proteins. The present invention also relates to compositions comprising such interferon-associated antigen binding proteins, nucleic acids, vectors and vector systems. The novel interferon-associated antigen binding proteins afford beneficial improvements over the current state of the art, for example in that they effectively disrupt viral replication and thereby reduce HBV viral load. Thus, the present invention also provides medical uses of such interferon-associated antigen binding proteins, nucleic acids, vectors, vector systems and compositions, e.g., in the treatment of hepatitis B virus (HBV) infection and/or for decreasing one or more symptoms of HBV infection in a subject. The present invention further provides host cells comprising such nucleic acids, vectors and vector systems as well as methods of making the interferon-associated antigen binding proteins according to the invention using said host cells.

公开(公告)号：US20230183308A1

公开(公告)日：2023-06-15

申请号：US18068104

申请日：2022-12-19

申请人： CytomX Therapeutics, Inc.

发明人： Nancy E. Stagliano ,  James W. West ,  Kathryn Kamath ,  Paul H. Bessette ,  Jason G. Sagert

IPC分类号： C07K14/56 ,  C07K14/00 ,  C07K14/555 ,  A61K47/64 ,  A61K47/65 ,  C07K19/00 ,  C07K14/565 ,  C07K14/57 ,  C07K16/00 ,  G01N33/68 ,  C07K14/705 ,  C12N15/10

CPC分类号： C07K14/56 ,  A61K47/64 ,  A61K47/65 ,  C07K14/00 ,  C07K14/57 ,  C07K14/555 ,  C07K14/565 ,  C07K14/705 ,  C07K16/00 ,  C07K19/00 ,  C12N15/1037 ,  G01N33/6866 ,  A61K38/00

摘要： A proprotein containing a functional protein coupled to a peptide mask that inhibits binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics. Proproteins containing a peptide mask can display a longer in vivo or serum half-life than the corresponding functional protein not containing a peptide mask.

公开(公告)号：US11352404B2

公开(公告)日：2022-06-07

申请号：US16631961

申请日：2018-07-24

申请人： RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

发明人： Sergei V. Kotenko ,  Raymond B. Birge ,  Viralkumar Rameshkumar Davra

IPC分类号： C07K19/00 ,  C07K14/555 ,  A61P35/00 ,  C07K14/71 ,  A61K38/00

摘要： Fusion molecules of a cytokine or portion thereof and a polypeptide which targets the fusion protein to phosphatidylserine, pharmaceutical compositions thereof, and methods for their use in targeting a cytokine or portion thereof to a pathological site and treating a disease or condition responsive to cytokine treatment are provided.

公开(公告)号：US11197915B2

公开(公告)日：2021-12-14

申请号：US15200813

申请日：2016-07-01

申请人： OPKO Biologies Ltd.

发明人： Fuad Fares ,  Udi Eyal Fima

IPC分类号： A61K38/27 ,  C07K14/61 ,  C07K14/59 ,  A61K38/24 ,  C07K14/555 ,  C07K14/505 ,  A61K47/02 ,  A61K47/12 ,  G01N33/74

摘要： CTP-modified human growth hormone polypeptides and pharmaceutical formulations and pharmaceutical compositions comprising the same and methods of producing, and using the same are disclosed.

公开(公告)号：US11168125B2

公开(公告)日：2021-11-09

申请号：US16518642

申请日：2019-07-22

申请人： BIOVERATIV THERAPEUTICS INC.

发明人： Robert T. Peters ,  Adam R. Mezo ,  Daniel S. Rivera ,  Alan J. Bitonti ,  Susan C. Low

IPC分类号： C07K14/755 ,  C07K14/475 ,  C07K14/505 ,  C07K14/555 ,  C07K14/56 ,  C07K14/745 ,  C07K16/00 ,  C12N9/64 ,  A61K47/68 ,  C07K14/565 ,  C12N9/96 ,  A61K47/60 ,  C07K14/59 ,  C07K14/61 ,  C07K14/705 ,  A61K47/64 ,  A61K38/00

摘要： The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

公开(公告)号：US11131671B2

公开(公告)日：2021-09-28

申请号：US16238582

申请日：2019-01-03

申请人： MeMed Diagnostics Ltd.

发明人： Eran Eden ,  Kfir Oved ,  Assaf Cohen-Dotan ,  Roy Navon ,  Olga Boico ,  Gali Kronenfeld ,  Meital Paz ,  Ellen Bamberger

IPC分类号： C07K14/525 ,  C07K14/555 ,  C07K14/575 ,  G01N33/52 ,  G01N33/53 ,  G01N33/535 ,  G01N33/547 ,  G01N33/68 ,  G01N33/569 ,  G01N33/50 ,  C07K14/54 ,  C07K16/12 ,  C07K16/24 ,  C07K16/26 ,  G01N33/577 ,  G16B20/00 ,  G16B40/00

摘要： Methods of diagnosing infections are disclosed. In one embodiment, the method comprises measuring the amount of each of the polypeptides TRAIL, CRP, IP10 and at least one additional polypeptide selected from the group consisting of IL-6 and PCT.